Goldman Small Cap Research initiates coverage on NEWCARDIO, INC. (NWCI.OB) with Speculative Buy Rating (NAB:NWCI)
Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has initiated coverage of NewCardio, Inc. (NWCI.OB), a publicly-traded cardiac diagnostic services company, with a Speculative Buy recommendation.
Goldman Small Cap Research has completed a Goldman Select Research report on the Company and believes that NewCardio’s cardiovascular diagnostic platform is a game-changing, disruptive technology that positions the Company to capture market share over the next 24 months.
NewCardio’s first three solutions represent a $5 billion annual market. NewCardio has already begun marketing its flagship cardiac safety product and its offerings for the urgent care and chronic care space represent novel offerings with large, addressable applications.
According to Goldman Small Cap Research analyst Rob Goldman, “When comparing NewCardio’s positioning with its market capitalization, we proffer that the Street is not only heavily discounting the prospects for large market share gains in the Cardiac safety arena pending evidence of revenue, but that it is essentially assigning a zero value on the other products, and limited value on the potential repeat successes for the Company’s management team. As investors become more familiar with the NewCardio story, and management continues to execute, this news-driven stock could reach our price target of $4.00.”
A copy of the report is available at the Company’s website, www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces stock market research reports. The Firm produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while performance maybe tracked separately, the same coverage criteria is utilized in determining coverage of all stocks in both research formats.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report’s full disclosures and analyst background fund on our website before investing. To download our research or for more information, visit http://www.goldmanresearch.com/">www.goldmanresearch.com.
NewCardio, Inc. NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). Â NewCardio's three-dimensional ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. Â NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development.
http://feeds.feedburner.com/~ff/BaystreetNewswire?a=P-iCGA2h0c0:NU_OMFpPhM0:yIl2AUoC8zA">
http://feeds.feedburner.com/~ff/BaystreetNewswire?d=yIl2AUoC8zA" border="0">
http://feeds.feedburner.com/~ff/BaystreetNewswire?a=P-iCGA2h0c0:NU_OMFpPhM0:F7zBnMyn0Lo">
http://feeds.feedburner.com/~ff/BaystreetNewswire?i=P-iCGA2h0c0:NU_OMFpPhM0:F7zBnMyn0Lo" border="0">
http://feeds.feedburner.com/~ff/BaystreetNewswire?a=P-iCGA2h0c0:NU_OMFpPhM0:7Q72WNTAKBA">
http://feeds.feedburner.com/~ff/BaystreetNewswire?d=7Q72WNTAKBA" border="0">
http://feeds.feedburner.com/~ff/BaystreetNewswire?a=P-iCGA2h0c0:NU_OMFpPhM0:V_sGLiPBpWU">
http://feeds.feedburner.com/~ff/BaystreetNewswire?i=P-iCGA2h0c0:NU_OMFpPhM0:V_sGLiPBpWU" border="0">
http://feeds.feedburner.com/~ff/BaystreetNewswire?a=P-iCGA2h0c0:NU_OMFpPhM0:qj6IDK7rITs">
http://feeds.feedburner.com/~ff/BaystreetNewswire?d=qj6IDK7rITs" border="0">
http://feeds.feedburner.com/~ff/BaystreetNewswire?a=P-iCGA2h0c0:NU_OMFpPhM0:l6gmwiTKsz0">
http://feeds.feedburner.com/~ff/BaystreetNewswire?d=l6gmwiTKsz0" border="0">
http://feeds.feedburner.com/~ff/BaystreetNewswire?a=P-iCGA2h0c0:NU_OMFpPhM0:gIN9vFwOqvQ">
http://feeds.feedburner.com/~ff/BaystreetNewswire?i=P-iCGA2h0c0:NU_OMFpPhM0:gIN9vFwOqvQ" border="0">
http://feeds.feedburner.com/~ff/BaystreetNewswire?a=P-iCGA2h0c0:NU_OMFpPhM0:TzevzKxY174">
http://feeds.feedburner.com/~ff/BaystreetNewswire?d=TzevzKxY174" border="0">
http://feeds.feedburner.com/~ff/BaystreetNewswire?a=P-iCGA2h0c0:NU_OMFpPhM0:dnMXMwOfBR0">
http://feeds.feedburner.com/~ff/BaystreetNewswire?d=dnMXMwOfBR0" border="0">
